Marielle E. Yohe, M.D., Ph.D.

Assistant Clinical Investigator

Pediatric Oncology Branch

NCI/CCR

Building 10-CRC, Room 1-W-5817
Bethesda, MD 20892

240-760-7436

marielle.yohe@nih.gov

Research Topics

More than 30% of all human malignancies are driven by mutant RAS isoforms. In addition to well characterized roles in malignant transformation and tumor progression, oncogenic RAS is also able to block differentiation within a cancer cell. We have previously shown that inhibiting the RAS-RAF-MEK-ERK MAP kinase pathway restores the differentiation of rhabdomyosarcoma cells by affecting the transcription of the master transcription factor, MYOG. Current laboratory projects include characterizing the effect of oncogenic RAS on the differentiation of neuroblastoma cells and identifying mechanisms by which rhabdomyosarcoma cells acquire resistance to MAP kinase pathway inhibitors. In addition, the laboratory is engaged in translational research aimed at identifying additional RAS-directed therapeutics for pediatric cancers.

Biography

After completing her undergraduate work at Wellesley College, Dr. Yohe received her M.D. and Ph.D from the University of North Carolina at Chapel Hill. She did her graduate work in the laboratory of Dr. John Sondek in the Department of Pharmacology. In this work, she addressed how truncation of Dbl-family Rho guanine nucleotide exchange factors leads to their aberrant activation. She completed her internship and residency in pediatrics at Connecticut Children's Medical Center in Hartford, CT, followed by fellowship training at the combined National Cancer Institute - Johns Hopkins University Hematology/Oncology program. She did her postdoctoral work in the laboratory of Dr. Javed Khan in the Genetics Branch of the CCR. Dr. Yohe is board certified in General Pediatrics (2013) and Pediatric Hematology/Oncology (2017). She is the recipient of an Alex's Lemonade Stand Foundation Young Investigator Award.

Selected Publications

  1. Gryder BE, Yohe ME, Chou HC, Zhang X, Marques J, Wachtel M, Schaefer B, Sen N, Song Y, Gualtieri A, Pomella S, Rota R, Cleveland A, Wen X, Sindiri S, Wei JS, Barr FG, Das S, Andresson T, Guha R, Lal-Nag M, Ferrer M, Shern JF, Zhao K, Thomas CJ, Khan J. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. Cancer Discov. 2017;7(8):884-899.

  2. Shern JF, Yohe ME, Khan J. Pediatric Rhabdomyosarcoma. Crit Rev Oncog. 2015;20(3-4):227-43.

  3. Chen L, Shern JF, Wei JS, Yohe ME, Song YK, Hurd L, Liao H, Catchpoole D, Skapek SX, Barr FG, Hawkins DS, Khan J. Clonality and evolutionary history of rhabdomyosarcoma. PLoS Genet. 2015;11(3):e1005075.

  4. Yohe ME, Rossman K, Sondek J. Role of the C-terminal SH3 domain and N-terminal tyrosine phosphorylation in regulation of Tim and related Dbl-family proteins. Biochemistry. 2008;47(26):6827-39.

  5. Yohe ME, Rossman KL, Gardner OS, Karnoub AE, Snyder JT, Gershburg S, Graves LM, Der CJ, Sondek J. Auto-inhibition of the Dbl family protein Tim by an N-terminal helical motif. J Biol Chem. 2007;282(18):13813-23.


This page was last updated on September 18th, 2017